Editas Medicine
EDIT
238 hedge funds and large institutions have $1.61B invested in Editas Medicine in 2020 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 77 increasing their positions, 50 reducing their positions, and 17 closing their positions.
258% more call options, than puts
Call options by funds: $47.4M | Put options by funds: $13.2M
235% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 17
76% more capital invested
Capital invested by funds: $912M → $1.61B (+$696M)
54% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 50
20% more funds holding
Funds holding: 199 → 238 (+39)
5.12% more ownership
Funds ownership: 83.69% → 88.82% (+5.1%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$57.8M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$36.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$27.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.4M |
| 5 |
BlackRock
New York
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTP
Global Thematic Partners
New York
|
-$8M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$7.83M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$3M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$2.87M |
| 5 |
Renaissance Technologies
New York
|
-$2.63M |
EDIT Hedge Fund Activity: Q2 2020 in Review
238 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2020, worth a combined $1.61B — up 76% from $912M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new EDIT positions and 17 closed out — a net gain of 40 holders — while 77 added to existing stakes and 50 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $57.8M. The largest seller was Global Thematic Partners, exiting entirely with an estimated $8M sold.
- 238 institutional investors held Editas Medicine (EDIT) as of Q2 2020, up from 199 in Q1 2020.
- Funds reported $1.61B of Editas Medicine stock for Q2 2020, up 76% quarter-over-quarter.
- 57 funds opened new Editas Medicine positions in Q2 2020 and 17 closed out, a net change of +40 holders.
- The largest Editas Medicine buyer in Q2 2020 was ARK Investment Management, an estimated $57.8M added.
- The largest Editas Medicine seller in Q2 2020 was Global Thematic Partners, an estimated $8M sold.
Based on aggregated 13F filings for Q2 2020.